As general-purpose large language models (LLMs) gain traction across pharmaceutical operations, companies face a critical architectural choice: should pharmacovigilance systems leverage broadly-trained foundation models, or purpose-built domain-specific AI?
ArcaScience conducted a comprehensive benchmark study across 12,000+ adverse event reports from FAERS, EudraVigilance, and clinical trial safety databases, comparing domain-specific models trained on pharmacovigilance data against leading general-purpose LLMs including GPT-4, Claude, and open-source alternatives.
The results demonstrate that domain-specific, purpose-trained models outperform general LLMs by 34% in adverse event extraction accuracy, 47% in MedDRA coding precision, and 28% in causality assessment agreement with expert pharmacovigilance reviewers. Perhaps most critically, domain models exhibited 94% fewer hallucinated adverse events—fabricated safety signals that could trigger unnecessary regulatory actions or compromise patient safety.
This whitepaper presents the empirical evidence, explains the architectural and training differences that drive performance gaps, and provides implementation guidance for pharmaceutical companies evaluating AI approaches for regulatory-grade pharmacovigilance operations. The findings have significant implications for both safety signal detection accuracy and computational cost efficiency.
Key Takeaways
Critical findings from 12,000+ adverse event reports across multiple data sources
34% Higher AE Extraction
Purpose-built named entity recognition (NER) models trained on medical adverse event corpora achieve F1 scores of 0.91 vs 0.68 for general LLMs. Domain models correctly identify drug-event relationships, seriousness criteria, and outcome classifications that general models frequently miss.
47% Better MedDRA Coding
Domain-trained hierarchical classification models achieve 92% accuracy mapping adverse events to correct MedDRA Preferred Terms (PTs) and System Organ Classes (SOCs), compared to 62% for general models. Critical for regulatory reporting and signal detection algorithms.
28% Improved Causality
Causality assessment models fine-tuned on expert-labeled PV cases show 83% agreement with senior medical reviewers using WHO-UMC criteria, versus 65% for general LLMs. Domain models better capture temporal relationships, dose-response patterns, and alternative explanations.
Regulatory Compliance
Domain models produce outputs conforming to ICH E2B(R3) data elements with 96% completeness, including mandatory fields for seriousness, expectedness, and causality. Validated against FDA and EMA submission requirements with full audit trails.
Reduced Hallucination
Domain models exhibit 94% fewer fabricated adverse events compared to general LLMs. Constrained decoding and medical vocabulary enforcement prevent generation of clinically implausible event descriptions or drug names, critical for patient safety and regulatory integrity.
Cost Efficiency
Smaller domain-specific models (125M-1.3B parameters) achieve superior performance at 60% lower inference costs than large general LLMs. Optimized model architectures enable on-premise deployment with standard GPU infrastructure, meeting pharma data residency requirements.
Table of Contents
-
Chapter 1
The AI Revolution in Pharmacovigilance
Evolution from rule-based systems to modern AI, current landscape of general vs domain-specific approaches, and strategic implications for pharma companies.
-
Chapter 2
General-Purpose LLMs: Capabilities and Limitations
Architectural overview of foundation models, training data characteristics, performance on medical NLP tasks, and fundamental constraints for regulatory applications.
-
Chapter 3
Domain-Specific Model Architecture and Training
Specialized architectures for pharmacovigilance, curated training datasets, fine-tuning methodologies, and validation frameworks for regulatory compliance.
-
Chapter 4
Benchmark Methodology and Dataset Description
Study design, 12,000+ case selection criteria across FAERS/EudraVigilance/trial databases, evaluation metrics, and expert reviewer protocols.
-
Chapter 5
Results: Adverse Event Extraction
Detailed performance analysis for NER tasks, entity recognition accuracy, relationship extraction, and error analysis by event type and data source.
-
Chapter 6
Results: MedDRA Coding and Signal Classification
Hierarchical classification performance, PT/SOC mapping accuracy, inter-rater agreement, and implications for automated signal detection algorithms.
-
Chapter 7
Results: Causality Assessment and Narrative Generation
WHO-UMC criteria application, expert agreement rates, hallucination frequency analysis, and quality assessment of generated case narratives.
-
Chapter 8
Recommendations and Implementation Guide
Decision framework for model selection, hybrid architecture considerations, deployment requirements, change management strategies, and ROI analysis.
Chapter 1: The AI Revolution in Pharmacovigilance
Excerpt from pages 2-4
From Rule-Based Systems to Modern AI
Pharmacovigilance has undergone three distinct technological eras over the past three decades. The first generation (1990s-2000s) relied on manual review processes and simple database queries. Medical reviewers manually coded adverse events to MedDRA terms, assessed causality using standardized criteria, and identified signals through laborious cross-referencing of case reports.
The second generation (2000s-2015) introduced rule-based automation and statistical algorithms. Systems like WHO VigiBase implemented disproportionality analysis methods (PRR, ROR, BCPNN) to systematically identify adverse drug reactions occurring more frequently than expected. Natural language processing tools emerged to extract structured data from unstructured case narratives, though these systems depended on hand-crafted rules and medical dictionaries that required constant maintenance and struggled with linguistic variation.
The third generation (2015-present) leverages deep learning and transformer-based language models. These AI systems learn patterns directly from large volumes of adverse event data, adapting to new terminology, drug names, and adverse event descriptions without explicit programming. However, this generation has fractured into two competing architectural paradigms: general-purpose foundation models trained on broad corpora, and domain-specific models trained explicitly on pharmacovigilance data.
The General LLM Promise
Large language models like GPT-4, Claude, and Llama have demonstrated remarkable capabilities across diverse NLP tasks. Their broad training enables zero-shot and few-shot learning—performing new tasks with minimal examples. For pharmaceutical companies, this versatility is appealing: a single model could theoretically handle adverse event extraction, MedDRA coding, causality assessment, narrative generation, and regulatory document drafting.
Commercial LLM APIs offer rapid deployment with minimal upfront investment. No model training, no specialized ML expertise, no GPU infrastructure. A safety scientist can experiment with ChatGPT or Claude, passing in a case narrative and receiving structured adverse event data within seconds. Early pilots have shown impressive results on carefully selected test cases.
Yet as pharmaceutical companies move from proof-of-concept pilots to production deployment at scale—processing tens of thousands of cases annually for regulatory submissions—critical limitations emerge. General LLMs exhibit inconsistent performance on medical terminology, particularly for less common adverse events and rare disease contexts. They generate plausible-sounding but factually incorrect MedDRA codes. They hallucinate adverse events not present in source narratives. They struggle to apply nuanced causality criteria that require deep pharmacological knowledge.
The Domain-Specific Alternative
Domain-specific AI takes a fundamentally different approach. Rather than training a massive general-purpose model on internet text and then hoping it performs well on pharmacovigilance, domain models are purpose-built from the ground up for adverse event data. They use specialized architectures optimized for medical entity recognition and hierarchical classification. They're trained exclusively on curated pharmacovigilance datasets: FAERS cases, EudraVigilance reports, clinical trial safety data, labeled MedDRA mappings, and expert-assessed causality judgments.
This focused training produces models that deeply understand pharmacovigilance-specific patterns. They recognize medical abbreviations, interpret temporal sequences of adverse events, apply WHO-UMC causality criteria consistently, and map events to MedDRA codes with high accuracy. Crucially, they can be validated against regulatory requirements—a process difficult to impossible for black-box commercial LLMs whose training data and decision processes are opaque.
The tradeoff is specialization: domain models excel at pharmacovigilance tasks but cannot handle general business writing or customer support. For pharmaceutical safety operations, this is not a limitation but a feature. The question this benchmark study addresses is whether this specialization delivers measurably better outcomes for the specific high-stakes tasks that determine drug safety decisions.
Chapter 5: Results—Adverse Event Extraction
Excerpt from pages 9-11
Overall Performance Comparison
We evaluated six AI systems across 12,482 adverse event case reports: ArcaScience's domain-specific NER ensemble (the "AS Model"), three leading commercial general-purpose LLMs (GPT-4, Claude 3 Opus, Gemini Pro), and two open-source models fine-tuned on general medical corpora (BioGPT, PubMedBERT). Each system processed identical case narratives and extracted structured adverse event data including drug names, event descriptions, onset timing, outcome, and seriousness indicators.
Adverse Event Extraction Performance (F1 Scores)
The domain-specific AS Model achieved an F1 score of 0.91, representing a 34% improvement over the best general-purpose LLM (Claude 3 Opus at 0.69) and 20% improvement over medical-domain-adapted models (PubMedBERT at 0.76). This performance gap is statistically significant (p < 0.001) and consistent across all subgroups analyzed.
Error Analysis: Where General LLMs Fail
Manual review of 500 randomly sampled errors revealed systematic patterns in general LLM failures:
1. Medical Abbreviation Misinterpretation (28% of errors): General LLMs frequently misinterpreted context-dependent medical abbreviations. For example, "MI" was incorrectly expanded as "myocardial infarction" in a psychiatric case where it referred to "motivational interviewing." The domain model correctly distinguished contexts through pharmacovigilance-specific training.
2. Temporal Relationship Errors (23% of errors): General LLMs struggled to correctly associate adverse events with specific drugs in polypharmacy cases. When a narrative described multiple medications and multiple events with different onset timings, general models frequently attributed events to the wrong drug or failed to capture the temporal sequence. Domain models explicitly encode temporal reasoning.
3. Seriousness Criteria Misapplication (19% of errors): Regulatory criteria for "serious" adverse events (death, life-threatening, hospitalization, disability, congenital anomaly, medically important) require precise interpretation. General LLMs incorrectly classified routine hospitalizations for scheduled procedures as serious AEs, or failed to recognize medically important events that required intervention to prevent serious outcomes.
4. Outcome Classification Ambiguity (17% of errors): Distinguishing between outcomes like "recovering/resolving" versus "recovered/resolved" has regulatory implications for ongoing safety monitoring. General LLMs often conflated these categories or failed to extract outcome information when expressed indirectly.
5. Hallucinated Events (13% of errors): Most concerning, general LLMs occasionally generated adverse events not present in source narratives. In 3.2% of cases, GPT-4 invented drug names or adverse event terms that appeared medically plausible but were factually incorrect. Domain models, with constrained vocabularies and validation layers, exhibited hallucination rates 94% lower (0.2% of cases).
Performance by Data Source
Performance varied by data source complexity. For highly structured FAERS reports with standardized fields, even general LLMs achieved acceptable extraction accuracy (F1 ~0.75). However, for free-text clinical trial narratives and complex EudraVigilance reports with embedded medical histories, the performance gap widened dramatically. Domain models maintained consistent F1 scores above 0.88 across all sources, while general LLMs dropped to F1 0.52-0.61 on the most complex narratives.
This finding has critical implications: pharmaceutical companies cannot rely on general LLMs for the most challenging cases that consume disproportionate medical reviewer time—precisely where AI assistance would provide maximum value. Domain models deliver consistent performance across the full spectrum of case complexity.
Benchmark Study Impact
Quantified performance differences across 12,000+ adverse event reports
Domain-specific models outperform general LLMs by 34% in adverse event extraction F1 scores (0.91 vs 0.68)
94% reduction in fabricated adverse events compared to general LLMs (0.2% vs 3.2% hallucination rate)
Benchmark dataset spanning FAERS, EudraVigilance, and clinical trial safety databases
Related Whitepapers
Signal Detection at Scale: Methods and Validation
Technical deep-dive on PRR, ROR, MGPS, BCPNN methods enhanced with deep learning for 3x faster signal identification.
View Whitepaper →The ArcaScience Methodology: AI-Driven BRA
Comprehensive overview of the platform's scientific foundation, 24 AI model taxonomy, and BRAT framework implementation.
View Whitepaper →Automating PSUR/PBRER: A Technical Guide
ICH E2C(R2) alignment and automation methodology for submission-ready document generation with full traceability.
View Whitepaper →Download the Full Whitepaper
Get the complete 16-page benchmark study with detailed performance metrics, error analysis, cost comparisons, and implementation recommendations.
Download PDFAccess the Whitepaper
Please provide your information to download this resource. We'll also send you relevant insights on AI in pharmacovigilance.